The new data could broaden the clinical use of palbociclib – and other drugs that work in the same way – beyond breast cancer to include many other tumour types as well.
Read More
Takeda’s Alunbrig has been approved in Europe as a treatment for a specific group of lung cancer patients, but access to the drug in the UK remains uncertain.
Read More
Draft guidelines from the National Institute for Health and Care Excellence do not recommend NHS funding for Takeda’s lung cancer drug Alunbrig.
Read More
Takeda’s Alunbrig cut the risk of disease progression or death by more than 50% compared to Pfizer’s Xalkori in adults with ALK+ non-small cell lung cancer.
Read More
Takeda’s Alunbrig has beaten Pfizer’s Xalkori on progression-free survival (PFS) in a Phase III trial testing its efficacy as a front-line treatment for ALK-positive lung cancer.
Read More
The Scottish Medicines Consortium has approved NHS funding for six new therapies, offering patients new options for leukaemia, epilepsy, lung cancer, plaque psoriasis, and carcinoid syndrome-related diarrhea.
Read More
The National Institute for Health and Care Excellence has turned down NHS funding for Roche’s Alecensa as a first-line treatment for lung cancer.
Read More
Pfizer’s Xalkori has been turned away by the National Institute for Health and Care Excellence to treat ROS1-positive advanced non-small cell lung cancer.
Read More
Roche’s Alecesna has been cleared for use in Europe as a first-line treatment for ALK-positive non-small cell lung cancer (NSCLC), offering a new option for patients newly diagnosed with the disease.
Read More
UK patients with a rare form of lung cancer will be able to access Roche’s Alecensa without the need for prior chemotherapy before official approval is obtained, following its inclusion in the country’s Early Access to Medicines Scheme.
Read More
Takeda Pharmaceuticals has bagged approval for Alunbrig in the US as a treatment for a specific group of lung cancer patients.
Read More
Roche has presented late-stage data showing that its Alecensa was superior to Pfizer’s Xalkori on progression-free survival in patients with a specific type of lung cancer.
Read More
